154 related articles for article (PubMed ID: 12775740)
1. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.
Tremblay PB; Kaiser R; Sezer O; Rosler N; Schelenz C; Possinger K; Roots I; Brockmoller J
J Clin Oncol; 2003 Jun; 21(11):2147-55. PubMed ID: 12775740
[TBL] [Abstract][Full Text] [Related]
2. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Perwitasari DA; Wessels JA; van der Straaten RJ; Baak-Pablo RF; Mustofa M; Hakimi M; Nortier JW; Gelderblom H; Guchelaar HJ
Jpn J Clin Oncol; 2011 Oct; 41(10):1168-76. PubMed ID: 21840870
[TBL] [Abstract][Full Text] [Related]
3. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
4. Do variations in the 5-HT3A and 5-HT3B serotonin receptor genes (HTR3A and HTR3B) influence the occurrence of postoperative vomiting?
Rueffert H; Thieme V; Wallenborn J; Lemnitz N; Bergmann A; Rudlof K; Wehner M; Olthoff D; Kaisers UX
Anesth Analg; 2009 Nov; 109(5):1442-7. PubMed ID: 19713259
[TBL] [Abstract][Full Text] [Related]
5. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
Kaiser R; Sezer O; Papies A; Bauer S; Schelenz C; Tremblay PB; Possinger K; Roots I; Brockmöller J
J Clin Oncol; 2002 Jun; 20(12):2805-11. PubMed ID: 12065557
[TBL] [Abstract][Full Text] [Related]
6. Association of 5-HT3B Receptor Gene Polymorphisms with the Efficacy of Ondansetron for Postoperative Nausea and Vomiting.
Kim MS; Lee JR; Choi EM; Kim EH; Choi SH
Yonsei Med J; 2015 Sep; 56(5):1415-20. PubMed ID: 26256989
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
8. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists.
Kaiser R; Tremblay PB; Sezer O; Possinger K; Roots I; Brockmöller J
Pharmacogenetics; 2004 May; 14(5):271-8. PubMed ID: 15115912
[TBL] [Abstract][Full Text] [Related]
10. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
11. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
12. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Lajolo PP; de Camargo B; del Giglio A
Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists].
Abenhardt W; Bosse D; Böning L; Bojko P; Hitz H; Völkl S; Fromm M; Mittermüller J; Göldel N; Schick HD; Dietzfelbinger H; Hinke A
Dtsch Med Wochenschr; 2006 Dec; 131(48):2707-12. PubMed ID: 17123235
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Takenaka M; Okamoto Y; Ikeda K; Hashimoto R; Ueda T; Kurokawa N; Takagi T; Uejima E
Gan To Kagaku Ryoho; 2007 Mar; 34(3):403-7. PubMed ID: 17353632
[TBL] [Abstract][Full Text] [Related]
15. [An outline of 5-HT3 receptor antagonists (1)--In pharmacological actions].
Tsukagoshi S; Ohta J; Taguchi T
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2108-14. PubMed ID: 8239673
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
Slatkin NE
J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
[TBL] [Abstract][Full Text] [Related]
17. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
19. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
20. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
